.png){kind=icon}
.png){kind=icon}
Return
HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness
.png){kind=icon}
PRE
AI
S
A
A
DOI：10.1016/j.smim.2025.102004.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• HCC cells that originate from HBV-infected hepatocytes express HBV antigens. • HBV-specific TCRs recognise HCC cells with HBV-DNA integration. • Side effects observed after HBV-specific TCR T-cell therapy in patients with primary HBV-HCC were manageable. • Clinical efficacy of adoptive transfer of HBV-specific TCR T cells has been observed in selected patients. • Mechanisms of T cell epitope spreading have been observed following adoptive transfer of HBV-specific TCR T cells.
Journal
IF:
7.8
Papers:
1.5K
Citations:
7.3K
Organization
No organization information available
Cited Papers